![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Additional Files]](https://mdc-test.eprints-hosting.org/style/images/fileicons/other.png) |
Other (Additional Files)
634kB |
| Item Type: | Review |
|---|---|
| Title: | Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification |
| Creators Name: | Puntmann, V.O., Valbuena, S., Hinojar, R., Petersen, S.E., Greenwood, J.P., Kramer, C.M., Kwong, R.Y., McCann, G.P., Berry, C. and Nagel, E. |
| Abstract: | Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen. |
| Keywords: | Cardiac Magnetic Resonance, Imaging, Biomarker, Position Paper, SCMR |
| Source: | Journal of Cardiovascular Magnetic Resonance |
| ISSN: | 1097-6647 |
| Publisher: | BioMed Central |
| Volume: | 20 |
| Number: | 1 |
| Page Range: | 67 |
| Date: | 20 September 2018 |
| Additional Information: | Jeannette Schulz-Menger is a member of the SCMR Clincial Trial Writing Group. |
| Official Publication: | https://doi.org/10.1186/s12968-018-0484-5 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
